

REMARKS

The teleconferences with the Examiner on August 29, 2006, October 11, 2006 and October 18, 2006 are acknowledged, with appreciation. The Examiner is understood to have advised the undersigned during the teleconference of August 29, 2006 that the claims would be allowable if the final phrase of claims 18 and 19 was added to claim 20, if the treosulfan derivatives of claims 18-20 were revised to recite the specific compounds of claims 24-26 and if claims 36-38 were revised to recite the substances of claims 39-41. In a further teleconference with the Examiner on October 11, 2006, the Examiner is understood to have advised the undersigned that amendment of the claims as presented herein would place the application in condition for allowance.

The claims have been amended as suggested by the Examiner, along with correction of obvious and inadvertent typographical errors. The specification has also been amended to correct the inadvertent typographical errors in the recited compounds. Moreover, the recitation of "interferon-" has been corrected to recite "interferon- β ". The error is believed to have been caused by a printing error. One of ordinary skill in the art will appreciate however that interferon- β is an immune modulating agent, as described on page 1, last sentence, of the specification. A substitute specification is attached. No new matter has been added.

New dependent claims 45-56, which are similar to claims 27-38 and 42-44, have been included and are submitted to be in condition for allowance.

Claims 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, and 44-56 are pending.

SASS
Appl. No. 10/524,144
October 19, 2006

A Notice of Allowance is requested. The Examiner is requested to contact the undersigned in the event anything further is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100